Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May 12;22(10):5094.
doi: 10.3390/ijms22105094.

The Potential Role of Flavonoids in Ameliorating Diabetic Cardiomyopathy via Alleviation of Cardiac Oxidative Stress, Inflammation and Apoptosis

Affiliations
Review

The Potential Role of Flavonoids in Ameliorating Diabetic Cardiomyopathy via Alleviation of Cardiac Oxidative Stress, Inflammation and Apoptosis

Fatin Farhana Jubaidi et al. Int J Mol Sci. .

Abstract

Diabetic cardiomyopathy is one of the major mortality risk factors among diabetic patients worldwide. It has been established that most of the cardiac structural and functional alterations in the diabetic cardiomyopathy condition resulted from the hyperglycemia-induced persistent oxidative stress in the heart, resulting in the maladaptive responses of inflammation and apoptosis. Flavonoids, the most abundant phytochemical in plants, have been reported to exhibit diverse therapeutic potential in medicine and other biological activities. Flavonoids have been widely studied for their effects in protecting the heart against diabetes-induced cardiomyopathy. The potential of flavonoids in alleviating diabetic cardiomyopathy is mainly related with their remedial actions as anti-hyperglycemic, antioxidant, anti-inflammatory, and anti-apoptotic agents. In this review, we summarize the latest findings of flavonoid treatments on diabetic cardiomyopathy as well as elucidating the mechanisms involved.

Keywords: diastolic dysfunction; flavanol; flavone; flavonol; isoflavone; systolic dysfunction.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Figures

Figure 1
Figure 1
Events in the development and progression of diabetic cardiomyopathy (DCM) initiated by diabetes-induced uncontrolled cardiac remodeling. The early stage of DCM mainly characterized by diastolic dysfunction will progress to late stage as systolic dysfunction appears, eventually leading to heart failure.
Figure 2
Figure 2
Summary of the mechanisms involved in the pathogenesis of diabetic cardiomyopathy. Hyperglycemia and hyperlipidemia resulting from insulin dysregulation induces excessive production of reactive oxygen and nitrogen species (ROS and RNS), generating oxidative stress in the cardiomyocytes. ROS also activates protein kinase C (PKC) pathways, which induces inflammation and cell apoptosis via mitogen-activated protein kinase (MAPK) pathways. Uncontrolled cardiomyocyte deaths lead to cardiac remodeling by cardiomyocyte hypertrophy and myocardial fibrosis as adaptive mechanisms to preserve the integrity of the heart. This structural alteration causes the heart to functionally regress as both diastolic and systolic dysfunction developed, conditions which define diabetic cardiomyopathy.
Figure 3
Figure 3
Chemical structures of different classes of flavonols. All flavanols classes share the same chemical bone, comprising two benzene rings (A and B) linked by a heterocyclic ring. Each flavonols are grouped into their classes based on the connection between the B and C rings as well as the hydoxylation and glycosylation patterns of the three main rings.
Figure 4
Figure 4
Potential of flavonoids in ameliorating diabetic cardiomyopathy, derived from their ability to combat diabetes-induced oxidative stress, inflammation, and apoptosis, which all play key roles in the structural and functional alterations in diabetic cardiomyopathy.

Similar articles

Cited by

References

    1. International Diabetes Federation . IDF Diabetes Atlas. 9th ed. International Diabetes Federation; Brussels, Belgium: 2019.
    1. Einarson T.R., Acs A., Ludwig C., Panton U.H. Prevalence of cardiovascular disease in type 2 diabetes: A systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovasc. Diabetol. 2018;17:1–19. doi: 10.1186/s12933-018-0728-6. - DOI - PMC - PubMed
    1. Institute for Public Health (IPH) National Health and Morbidity Survey 2015: Non-Communicable Diseases, Risk Factors & Other Health Problems. Volume II Insitute for Public Health, Ministry of Health Malaysia; Kuala Lumpur, Malaysia: 2015.
    1. Jia G., Hill M.A., Sowers J.R. Diabetic Cardiomyopathy: An Update of Mechanisms Contributing to This Clinical Entity. Circ. Res. 2018;122:624–638. doi: 10.1161/CIRCRESAHA.117.311586. - DOI - PMC - PubMed
    1. Paolillo S., Marsico F., Prastaro M., Renga F., Esposito L., De Martino F. Diabetic cardiomyopathy: Definition, diagnosis, and therapeutic implications. Heart Fail Clin. 2019;15:341–347. doi: 10.1016/j.hfc.2019.02.003. - DOI - PubMed

MeSH terms